OBJECTIVES: Assessing validity and reliability of end points used in docosahexanoic and arachidonic acids (DHA and ARA) infant formula supplementation trials as an example for addressing the impact of end-point selection and critical need for well-defined, reliable and validated clinical outcome assessments for neurocognitive assessment in neonates and infants. STUDY DESIGN: We searched eight electronic databases and reviewed all randomized, controlled human trials using DHA/ARA supplements with neurodevelopment clinical outcomes. We systematically evaluated the validity and reliability of end-point measures based on the criteria for studying nutritional additives recommended by the Institute of Medicine, criteria described in the Food and Drug Administration guidance for clinical outcome assessment, development and literature review.
INTRODUCTION
The selection of the primary end points or outcome measures influences the reliability, validity and ability to interpret the results of clinical trials. 1 To be informative, clinical trials should use primary end points and outcome measures that are well defined, valid, reliable and clinically relevant. 1 The academic investigators, pharmaceutical industries and regulatory agencies have recognized a lack of well-defined and reliable clinical outcome assessments for long-term neurocognitive outcomes, and thus there is a critical need for developing clinical outcome assessments to measure and predict neurocognitive function in clinical trials with neonates and infants. 2 For example, a large body of the infant formula docosahexanoic and arachidonic acids (DHA and ARA) supplementation trials has been conducted. In these clinical trials, many varieties of poorly defined and unreliable study end points were often used to assess neurodevelopmental outcomes, thus resulting in inconsistent study outcomes. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] For these reasons, the focus of this study is to discuss the issues associated with the validity and reliability of neurodevelopment end points, rather than the effects of DHA/ARA on neurodevelopmental outcomes.
Long-chain polyunsaturated fatty acids (LCPUFAs) are found in high proportions in the structural lipids of cell membranes, particularly those of the central nervous system, and their accretion primarily occurs during the last trimester of pregnancy and the first year of life. 18 Since 2002, LCPUFAs, particularly 22-carbon DHA and 20-carbon ARA, have been added to infant formula as supplements to simulate breast milk with the potential to benefit growth, visual acuity and neurodevelopmental outcome. Numerous clinical trials have been conducted in both term and preterm infants using a wide variety of study end points and outcome measures to assess the safety and effectiveness of DHA and ARA on neurodevelopment and visual acuity. [18] [19] [20] [21] However, these trials and many meta-analyses have not yielded consistent results in showing beneficial effects of adding DHA and ARA to infant formula. [18] [19] [20] [21] A major source of these inconsistent results or study outcomes appears to be methodological, notably the reliance on non-validated end points to determine neurocognitive effects. We addressed such issues associated with the visual acuity studies in the previous publication. 22 For these reasons, our current review only focuses on the evaluation of validity and reliability of the study end points and outcome measures for assessing neurodevelopment assessment. By contrast, study end points, such as weight, length velocity, head circumference and measures of body composition, are well-defined and validated end points used in many trials for assessing physical growth. [18] [19] [20] [21] These specific end-point measures have consistently demonstrated that DHA/ARA have no beneficial effects on physical growth of infants enrolled. [18] [19] [20] [21] 
METHODS

Data sources and study selection
Eight electronic databases (PubMed/ Medline, ISI web of Knowledge, Agricola, Pascal, Foodline, Food Science and Technology, Biosis previews and Embase) were used to search phrases such as 'infant formula/AND (DHA, ARA, AA, LCPUFA or LCFA). No language and time restrictions were applied during the search. The last search was conducted on 31 October 2014. To further increase the search coverage, we also reviewed the reference lists of initially retrieved literature to identify articles that were missed by the database search. The literature search was independently performed by H Sun and LS Bernstein, a Food and Drug Administration (FDA) librarian. Only randomized, controlled clinical trials with study end points addressing neurological development were considered for the review. Consensus was achieved by the two reviewers on inclusion of these trials in this study.
Review strategy for study end points and outcome measures
For clinical trials that test safety and effects of a new ingredient in infant formula, the Institute of Medicine recommends that the clinical end points, in addition to growth assessments, should include measurement of infant sensory-motor, cognitive, affective/emotional and neural function with instruments that follow recommended criteria. 23 With that in mind, the validity of the instruments identified in this study was evaluated based on the Institute of Medicine recommended criteria for the evaluation of the infant formula additives. Specifically, to be considered valid study outcome measures in human infant trials, the measures should be age appropriate, have predictive value for long-term consequences, be adequately sensitive, have documented brain-behavior links, assess specific function and be easy to administer. 23 The reliability and acceptability of these end-point measures and assessment methods were examined based upon the criteria for the psychometric standardization and psychometric properties that the FDA uses to evaluate neurodevelopment end points in the trials supporting the development applications of drugs and devices. [24] [25] [26] These criteria require that the instruments for the measurement of neurodevelopment end points should have adequate test and retest reliability, validity for the primary neurodevelopment measures, detailed description of the procedure, development of a large normative database and elimination of cultural influence. In summary, if a particular rating scale or cognitive test battery meets the above requirements and there is reasonable scientific support in the literature that the particular instrument has utility for the medical condition being evaluated in the clinical trial, it likely would be considered an acceptable end-point measure. The need for demonstrated utility in the scientific literature may be essential as data from previous studies are often used to calculate sample size and power estimates to determine statistical significance. Moreover, information from the scientific literature is essential to determine whether the magnitude of change is clinically meaningful. A change from baseline to end of treatment may meet statistical significance; however, that magnitude change may not be clinically meaningful unless there are available data indicating what constitutes a clinically meaningful change in function. [24] [25] [26] A descriptive summary table was used to extract the age group, study end points, outcomes and other relevant key data from each study and to serve as a basis for the construction of the trial outcome summary table that was used to demonstrate the impact of the end-point measures. The data extraction was independently conducted by two reviewers. To ensure the consistency of the review conducted by different reviewers, a template including age group, study design, end points, assessment methods and so on was predefined. The tables ( Supplementary Table 1a -c) were submitted as Supplementary Materials.
Neurodevelopment trial data were stratified as term and preterm infant exposure based upon the infant's age at the time of the LCPUFA supplementation. The preterm infant sub-group was further stratified into healthy preterm and preterm infant with concomitant medical conditions based upon their birth weight, gestational age and medical conditions.
RESULTS
Of 647 articles retrieved from the literature search, 479 articles relevant to infant formula and LCPUFA supplementation were identified. Twenty-nine studies in the areas of interest that met the eligibility criteria as described in the Methods section and were reviewed as shown in Figure 1 and Supplementary Table  1a -c. The definition of neurological development and assessment instruments were not consistent in different trials/publications. The end points used for neurodevelopment measures in 23 out of 29 original short-term studies included the Bayley Scale of Infant Development (BSID) I and II (n = 12), Brunet-Lezine test (n = 2), videotape infant's movements (n = 1), record time to milestones including sitting, crawling, standing and walking (n = 1), problemsolving test (n = 2), brainstem auditory-evoked potential (BAEP; n = 1), Touwen examination (n = 1), Fagan test of infant intelligence (n = 2) and visual habituation protocol (n = 1). Among the other six long-term follow-up studies reviewed, the end points included the Stanford-Binet (SB) IQ test (n = 1), Wechsler Preschool and Primary Scale of Intelligence (n = 4) and Bracken Basic Concept Scale (n = 1), which are generally scales of intellectual ability and typically do not change substantively in the short term.
The validity evaluation of the end-point measures Brain-behavior links. The accumulated scientific literature appears to support that the majority of tests listed above have a 'brain-behavior' link to the extent that underlying brain dysfunction or neurodevelopmental delay can be identified with all of these tests. For example, the age-equivalent score derived from the BSID results can determine whether the child is functioning at the appropriate chronological age. In addition, delayed response latencies or diminished amplitude to the Visual-Evoked Potential or BAEP could indicate possible demyelination or lack of neuronal development. Table 1 , the majority of the tests are not specific for any one neurological or neurodevelopmental disorder, although most of the instruments listed above likely have some degree of sensitivity for assessing neurodevelopmental progress.
Sensitivity and specificity. As shown in
Long-term predictive value. In general, scales of intellectual ability and developmental level are primarily designed to assess ability or functioning at a single point in time and compare the patient's scores with age-appropriate normative scores. Typically, intelligence quotient (IQ) and developmental assessment scales are not used to predict long-term outcomes. This was supported by our review of the literature, which did not identify any studies investigating the long-term predictive value of these scales in infant formula supplementation trials. The variability of human development even in neurologically normal individuals is quite heterogeneous and it is well established that rates of development can vary considerably in the absence of neurological insult or injury (for example, the so-called 'later bloomer' concept). Thus, the scales listed above do not appear to have any long-term predictive value.
Ease of administration. All of the scales listed above are relatively easy to administer if done by a qualified health professional. The BSID and SB scales have strict instructions for administering and End points for neonatal and infant neurocognitive measure scoring the various subtests in these scales. No deviations are allowed by the psychometrician in administering these tasks or the results are not considered valid. Moreover, the interpretation of the results of these scales must be completed by a doctoral level psychologist. Obviously, any neurological examination should be administered by a neurologist or a qualified neurological examiner. Evoked potential tests are dependent upon the qualifications of the technician who complete the electrode placement.
Review of reliability and acceptability of end-point measures. At the FDA, the acceptability of an end-point measure specifically for various rating scales or neurocognitive instruments is typically determined by both the scientific literature and the available data on the psychometric standardization and psychometric properties of the rating scale or cognitive test instrument. In general, all behavioral rating scales and objective cognitive test batteries need to undergo rigorous psychometric testing. Of the scales listed above, only BSID-III is being used in an Investigational New Drugs as a primary end-point measure. The other measures may have some utility as secondary or exploratory end-point measures; however, they often lack specificity for a particular medical disorder. Network and most randomized neonatal trials to assess neurodevelopment outcomes in infants and toddlers. 27 Mean scores of 100 with a standard deviation of 15 are considered as normal for the Mental Development Index and Psychomotor Development Index for BSID-II. 7 As shown in Table 2 , BSID-I and -II are valid end points for primary neurodevelopment measures, but do not have adequate measures to eliminate the confounding source resulted from the cultural influence. It is well known that, during the assessment procedure, the responses can be significantly altered based upon one's cultural background and/or ethnicity.
The BSID is now in its third revision (BSID-III). The BSID-III is designed for children between the ages of 1 month and 42 months, all races and all ethnicities. It is based upon developmental research and theory that identifies behaviors typifying normal development in young children. The BSID-III also provided developmental risk indicators that may detect atypical behaviors that warrant further evaluation (but does not provide a diagnosis). Normative information is based on a national standardization sample representative of the US population for infants 1 month to 42 Table 2 , the Brunet-Lezine test does not meet all of the above psychometric standardization requirements (for example, lack of a normative database). It is unlikely that the FDA would accept this scale as either a primary or a secondary end-point measure.
The SB IQ test, Wechsler Preschool and Primary Scale of Intelligence and Bracken Basic Concept Scale These are standardized tests to measure intellectual ability and yield an IQ score. These tests typically utilize a score of 100 as average with a standard deviation of 10. IQ scores are typically distributed as superior (IQ4120), above average (110 to 119), average (90 to 109), low average (80 to 89), borderline (70 to 79) and mentally retarded (o70). The SB test is one of the original tests developed to assess IQ. The SB measures five factors of cognitive ability: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual-Spatial Processing and Working Memory. Each of these factors is tested in two separate domains, verbal and nonverbal. The SB can be administered to individuals, ages 2 to 85+ years. The SB has been viewed as the 'gold standard' IQ test by which other more contemporary IQ tests have been validated against. The SB has robust psychometric standardization data and a large normative database (N = 4800).
These outcome assessments are rarely used as a primary outcome measure as this scale is a measure of general intelligence and not neurodevelopment like the BSID-III, as shown in Table 2 . The sample size requirements needed for a clinical trial using this scale as an end point would likely need to be considerable to demonstrate significant changes in IQ score.
The Touwen Infant Neurological Examination (TINE)
The TINE is an infant assessment technique, which includes not only the evaluation of traditional neurological signs, such as dysfunctional muscle tone regulation, abnormal reflexes or dysfunction of cranial nerves, but also has substantial attention to the quality of spontaneous motility in terms of variation and stereotype. The TINE includes information on the procedures of the assessment and the criteria for age-appropriate performance, but it does not provide information on criteria for dysfunction. However, the TINE does require the clinician to classify the results of the neurological examination as either normal, sub-optimal, minor neurological dysfunction or abnormal.
TINE has potential utility as an end-point measure; however, the specific scoring and quantification of this scale would need to be included in any FDA submission. Currently, this scale appears to be highly subjective. Therefore, some demonstration of inter-rater reliability would be required particularly in a multicenter clinical trial to assure consistency among the neurologist investigators as shown in Table 2 . The problem-solving test for age 9 to 10 months This test does not appear to be a commercially available or psychometrically standardized test. In the trials reviewed, the researchers indicated that infants sat on the parent's lap at the end of a table, and problems were presented on a tray: a barrier, a block of foam covered with blue fabric; a brown cloth; and a cover, a blue cloth. The goal object was a small toy. To familiarize the infants with the materials and the procedure, the infants were presented the barrier, cloths and toy on the tray individually, allowing two presentations of each object and 20 s for play. Infants next received pretests on the component steps of the three-step problem. In the first, they removed the barrier to retrieve the toy behind it; then they pulled the cloth to retrieve the toy placed on the far end; and in the third, pretest infants searched for the toy after they had seen it hidden under the cover. Infants were allowed 30 s to retrieve the toy, and played with the toy for 20 s before receiving the next trial. This test would not be an acceptable end-point measure as it lacks all the requirements for psychometric standardization as shown in Table 2 .
Brainstem auditory-evoked potential The BAEP test uses auditory stimuli to trigger an evoked response, which essentially is a characteristic waveform in which measurements of response latency and amplitude can be derived. The BAEP essentially can assist in determining the physiological maturation of the brainstem acoustic pathway. BAEP recordings are affected to a greater extent in neonates and children than adults by physiological factors and methodological aspects (for example, stimulation procedures, recording settings and so on), all of which need to be thoroughly evaluated in order to ensure the reliability of normative data and clinical interpretations. Importantly, the effect of age decreases over time and is greatest in neonates and early infancy.
The BEAP is used in the assessment of a variety of neurological conditions, such as multiple sclerosis, optic neuritis, occipital trauma, among others. Moreover, the methodology for measuring evoked response and latency varies considerably, which introduces a considerable source of error in the analyses of these variables. As shown in Table 2 , BAEP would be not acceptable as a primary neurodevelopment measure.
Videotaped infant movements
It does not appear to be any uniform methodology in the scientific literature with respect to standardized procedures for videotaping infant movements. It might have the potential to be a secondary or exploratory end-point measure. However, it is unclear if specific scores have been developed to determine impairment (and the degree of variability that is inherent in this type of assessment). In addition, a FDA application seeking approval as a drug or device utilizing this end point would need to include a specific protocol for the videotaping, including the use of the same equipment if the trial is multicenter and the specific methods for quantifying the infant movements.
Time to achieve developmental milestones The acquisition of various developmental milestones, such as sitting, crawling, standing and walking, are relatively well established but essentially considered to be less sensitive and specific as a developmental marker as there are multiple factors that can contribute to these specific developmental milestones, many of which are external to the actual developing nervous system (for example, environmental or parenting factors).
This assessment certainly has potential to be an end-point measure as these are fairly well developed and standardized. However, these end points may not be practical for a trial, which for some developmental milestones may include years rather than months. 
Fagan test of infant intelligence and visual habituation protocol
Fagan Test of infant intelligence consists of a series of familiarizations to visual stimuli (pictures of faces) followed by determinations of visual recognition memory in paired comparisons of familiar with stimuli. Information processing is determined from the number and duration of discrete looks during these paired comparisons. Visual habituation protocol was designed to test the cognitive performance of infants and was augmented with simultaneous measurement of heart rate. In visual habituation, the infant's visual and cardiac responses are assessed to repetitive stimulus presentations; the decline in responses to the stimuli is generally interpreted to indicate learning of the stimulus. Both tests would not be considered acceptable end-point measures as they lack the requirements for psychometric standardization.
Study outcomes of clinical trials assessing neurological development in human infants (N = 29) As shown in Table 3 , compared with standard infant formula, beneficial effects of DHA/ARA supplementation on neurodevelopment were reported in 2 out of 12 studies (17%) using BSID as compared with 8 out of 11 studies (73%) using other end-point measures. No beneficial effects of DHA/ARA supplementation on cognitive development were demonstrated in six long-term follow-up studies as shown in Table 4 . In addition, a partial neurological benefit (mental developmental index) was reported in one study using BSID. 7 No study used BSID-III as a primary endpoint measure. The descriptive summary tables were provided as supplementary materials with the study end points, outcomes and other relevant key data extracted from each study.
DISCUSSION
Although BSID-I and -II are commonly used and valid to identify early developmental delays that require intervention, they are not adequate to serve as primary end points for neurocognitive assessment in clinical trials with neonates and infants. The complex differences in end-point instruments complicate the claim that there are improved outcomes with DHA/ARA-supplemented infant formula trials. None of the end points examined is age-appropriate for neurocognitive assessment in neonates. In addition, the results of the trials reviewed cannot be used to predict a long-term benefit as the instruments used for these neurodevelopment end-point measures are not designed to determine long-term predictive values. Although not valid for neurodevelopment measurement, SB IQ test, Wechsler Preschool and Primary Scale of Intelligence-Revised version and Bracken Basic Concept Scale-revised version are valid to assess the cognitive development, a subset of neurodevelopment, of children, but not for neonates and infants. The BSID-III is an acceptable primary end-point measure in the registration trials in support of drug or device marketing application because of its latest revision to eliminate the potential cultural confounders. Similarly, the BSID-III is not adequate to assess neurocognitive function in neonates and infants that may be differentially affected by interventions or exposures, nutritional or otherwise, thus it is limited to evaluate infant cognition in the context of recent advances in developmental science.
Currently, development of well-defined, valid and reliable clinical outcome assessment that measures neurocognitive function in neonates and infants is critically needed to study safety and efficacy of medicine and food additives for this population. In general, clinical outcome assessment tools should be reliable, valid and able to detect clinically meaningful change in the outcome of interest. The collaboration of interested parties, including international regulatory bodies, pharmaceutical industry, academia and parent groups, in the development of adequate outcome measures for neurocognitive assessment in neonates and infants is highly encouraged. To facilitate development of publicly available scientific tools to address critical needs such as this, the FDA has initiated a drug development tool qualification program that provides a framework for the development and regulatory acceptance of scientific tools, including clinical outcome assessments, intended for well-specified clinical trial contexts of use. 24 Abbreviation: IQ, intelligence quotient.
End points for neonatal and infant neurocognitive measure As shown in Table 4 , available data are inadequate at the present time to conclude that DHA/ARA supplementation in infancy has a long-term meaningful beneficial effect upon cognitive development. Consistent with previous meta-analysis reports, [18] [19] [20] [21] 28, 29 available data are inadequate at the present time to conclude that DHA/ARA supplementation, for either term or preterm infants, has a clinically meaningful beneficial effect upon neurological development. There is an inadequate evidence base to recommend supplementation with these fatty acids.
In addition, there appear to be several methodological and cultural confounders, which also contribute to the inconsistent results reported in the literature. For instance, the outcomes of some trials 3, 4, 30 that demonstrated benefit can be confounded by cultural influences. For example, the Brunet-Lezine test with a normative database of French children was used to assess Italian children, or BSID with a normative database of American children was used to assess Taiwanese children. The confounder needs to be eliminated when selecting the study end points and outcome measures.
Clinical studies are needed if one is to prove neurocognitive effect attributable to a new ingredient added to infant formula. DHA and ARA are believed to influence neural function; hence, more specific cognitive assessment measures such as attentional capacity may prove to be more sensitive for assessing neurodevelopment with this mechanism. A consensus in the selection of the study end-point and assessment instruments for use in clinical trials is needed to determine the beneficial effects of infant formula supplementation. To demonstrate convincing evidence, the clinical trial, with a purpose of assessing DHA/ARA effect on infant's neurodevelopment, should select a well-defined primary neurodevelopment end-point measure and a validated instrument that has the properties of adequate test and retest reliability, validity for the end-point measures, detailed description of the procedure, development of a large normative database and elimination of cultural influence. In addition, dose selection is also crucial to demonstrate the effect of the testing substances. It has been speculated that the low dose of DHA/ARA might contribute to the lack of evidence for the beneficial effect. To determine the beneficial effect, if any, well-designed, randomized, doubleblinded, controlled trials with a well-defined, valid and reliable clinical outcome assessment as a primary neurodevelopment endpoint measurement would advance knowledge in this field.
